The deal ends an investigation by the SEC into certain accounting practices by Alere's foreign subsidiaries. The company also consented to a cease-and-desist order.
With data analytics and more specific billing codes, the government has improved its ability to identify medically unnecessary genetic testing and other fraudulent activity.
The preliminary approval is the penultimate step to bringing to a close a class action lawsuit accusing Celera of making false and misleading statements about its finances.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Investors are suing China Medical Technologies alleging the firm engaged in actions that artificially inflated its stock in violation of US securities law.
